Insights into the molecular mechanisms regulating vascular and immune metabolism in vascular diseases

PROJECT SUMMARY Atherosclerosis, the major cause of cardiovascular disease (CVD), is a chronic disease characterized by lipid retention and vascular inflammation. Endothelial cells (ECs), smooth muscle cells (SMCs) and macrophages are recognized to have a unique impact on the disease progression. It is recently recognized that specific

dysregulation of metabolic signaling pathways contributes to certain aspects of EC, macrophage and SMC homeostasis. For instance, during the process of atherosclerosis, ECs are exposed to a pro-inflammatory milieu that enhances glycolysis and reduces fatty acid oxidation in ECs and predisposes them to undergo

mesenchymal transition (EndMT), which may affect plaque stability. The implications of non-coding RNAs, including microRNAs (miRNAs), in cardiovascular disease is well recognized, representing the most rapidly evolving research field. Furthermore, miRNAs have emerged as critical regulators of cellular metabolism (e.g.

miR-33) and therefore can directly regulate EC metabolic responses that can determine the progression of atherosclerosis, although this aspect has not been elucidated yet. Moreover, miRNAs can promote the acquisition of mesenchymal markers (e.g. miR-21) that can in turn shape their metabolic response and

mesenchymal phenotype, thus affecting EC atherosclerotic phenotype. This has also not been investigated in detail. In this regard, similar mechanisms may be involved in the phenotypic regulation of SMC during atherosclerosis, and need to be explored as well. A vast literature has demonstrated that miRNAs play

important roles in macrophage functions by regulating macrophage inflammatory responses and lipid metabolism. Increasing evidence indicates that a substantial crosstalk exists between innate immune signaling and metabolic pathways. Macrophage activation and differentiation prominently feature the modulation of genes involved in general cellular metabolic activities. In this regard, downregulation of

cholesterol biosynthetic genes in classically activated macrophages is linked to regulation of inflammatory reactions elicited by macrophages. A critical outstanding question is how the dynamic interplay between cholesterol, cholesterol biosynthetic intermediates and cholesterol derivatives influences macrophage foam

cell formation and inflammation, which are key determinants of atherosclerosis progression. On the whole, this research program aims to elucidate different mechanisms that regulate cell-specific metabolic signaling pathways and how they are involved in the progression of atherosclerosis. Targeting cell-specific metabolic

processes could become another potential therapeutic targeting strategy for treating metabolic disorders.